Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.
A lack of profits can lead to trouble, but StockStory helps you identify the businesses that stand a chance of making it through. Keeping that in mind, here are three unprofitable companiesthat don’t make the cut and some better opportunities instead.
Wayfair (W)
Trailing 12-Month GAAP Operating Margin: -1.5%
Founded in 2002 by Niraj Shah, Wayfair (NYSE: W) is a leading online retailer of mass-market home goods in the US, UK, Canada, and Germany.
Why Does W Fall Short?
- Struggled with new customer acquisition as its active customers averaged 1.8% declines
- Estimated sales growth of 5.2% for the next 12 months is soft and implies weaker demand
- Gross margin of 30.2% is below its competitors, leaving less money to invest in areas like marketing and R&D
Wayfair’s stock price of $100.41 implies a valuation ratio of 19.5x forward EV/EBITDA. To fully understand why you should be careful with W, check out our full research report (it’s free for active Edge members).
Jack in the Box (JACK)
Trailing 12-Month GAAP Operating Margin: -1.2%
Delighting customers since its inception in 1951, Jack in the Box (NASDAQ: JACK) is a distinctive fast-food chain known for its bold flavors, innovative menu items, and quirky marketing.
Why Do We Pass on JACK?
- Weak same-store sales trends over the past two years suggest there may be few opportunities in its core markets to open new restaurants
- Day-to-day expenses have swelled relative to revenue over the last year as its operating margin fell by 6.5 percentage points
At $18.91 per share, Jack in the Box trades at 4.8x forward P/E. Check out our free in-depth research report to learn more about why JACK doesn’t pass our bar.
Myriad Genetics (MYGN)
Trailing 12-Month GAAP Operating Margin: -51%
Founded in 1991 as one of the pioneers in translating genetic discoveries into clinical applications, Myriad Genetics (NASDAQ: MYGN) develops genetic tests that assess disease risk, guide treatment decisions, and provide insights across oncology, women's health, and mental health.
Why Do We Steer Clear of MYGN?
- Sales trends were unexciting over the last two years as its 6% annual growth was below the typical healthcare company
- Push for growth has led to negative returns on capital, signaling value destruction, and its decreasing returns suggest its historical profit centers are aging
- Eroding returns on capital from an already low base indicate that management’s recent investments are destroying value
Myriad Genetics is trading at $6.15 per share, or 196.3x forward P/E. If you’re considering MYGN for your portfolio, see our FREE research report to learn more.
Stocks We Like More
If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.
Don’t wait for the next volatility shock. Check out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today.
